While cisplatin treatment alone significantly reduced tumor size, combination with the SMARCA4 targeting PROTAC AU-15330 resulted in a higher percentage of mice with reduced tumor size, reduced tumor proliferation, and increased immune infiltration. Here, SMARCA4 is linked to neoplasm.